Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 11/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | FABP6 | P51161 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8963556 | 0.88 | ALDH1A1 (0.57) | GBA1HTTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL8963072 | 0.85 | PRKCQ (0.48) | GBA1SMN1; SMN2ALDH1A1KDM4EPRKCQ | |
| SCHEMBL8964239 | 0.84 | ALDH1A1 (0.45) | GBA1HTTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL8963499 | 0.84 | SIGLEC9 (0.50) | HTTSMN1; SMN2ALDH1A1KDM4EPRKCQ | |
| SCHEMBL8963321 | 0.83 | ALDH1A1 (0.56) | GBA1SMN1; SMN2ALDH1A1KDM4EPRKCQ | |
| SCHEMBL8970170 | 0.83 | PRKCQ (0.71) | GBA1ALDH1A1PRKCQ | |
| SCHEMBL8963376 | 0.83 | PRKCQ (0.45) | HTTSMN1; SMN2ALDH1A1KDM4EPRKCQ | |
| SCHEMBL8963170 | 0.82 | PRKCQ (0.46) | SMN1; SMN2ALDH1A1KDM4EPRKCQ | |
| SCHEMBL8963549 | 0.82 | REV1 (0.48) | SMN1; SMN2ALDH1A1KDM4EPRKCQ | |
| SCHEMBL8963489 | 0.82 | CKS1B (0.47) | SMN1; SMN2ALDH1A1KDM4EPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | GBA1 1257/4885HTT 983/4885SMN1; SMN2 1649/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | GBA1 1257/4885HTT 983/4885SMN1; SMN2 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.